Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


gefitinib resistance ( 40 / 21 /
6
/
13
)
gemcitabine resistance ( 58 / 29 /
9
/
20
)
genomic instability ( 14 / 7 /
3
/
4
)
gluconeogenesis ( 4 / 2 /
0
/
2
)
5fluorouracil resistance ( 128 / 73 /
24
/
31
)
adhesion ( 55 / 30 /
8
/
17
)
Adriamycin (Adr) resistance ( 30 / 16 /
4
/
10
)
aerobic glycolysis ( 83 / 42 /
12
/
29
)
Afatinib resistance ( 2 / 1 /
0
/
1
)
AKT signaling ( 327 / 165 /
55
/
107
)
anchorage-independent growth ( 39 / 20 /
11
/
8
)
Angiogenesis ( 300 / 155 /
51
/
94
)
Anoikis ( 28 / 15 /
5
/
8
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 2079 / 1053 /
662
/
364
)
Autophagy ( 482 / 242 /
111
/
129
)
beta-catenin signaling ( 77 / 39 /
14
/
24
)
BMP signaling ( 233 / 126 /
72
/
35
)
Bone metastasis ( 26 / 15 /
3
/
8
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
Brain metastasis ( 2 / 1 /
0
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
BRCAness ( 2 / 1 /
1
/
0
)
Camptothecin resistance ( 3 / 2 /
0
/
1
)
cancer progression ( 16 / 9 /
5
/
2
)
carboplatin resistance ( 4 / 2 /
1
/
1
)
Castrate Resistance ( 27 / 16 /
9
/
2
)
cell cycle ( 262 / 137 /
46
/
79
)
cell cycle arrest ( 515 / 261 /
226
/
28
)
cell cycle progression ( 191 / 97 /
46
/
48
)
Cell growth ( 844 / 426 /
128
/
290
)
cell polarity ( 1 / 1 /
0
/
0
)
cell spreading ( 8 / 6 /
0
/
2
)
cell viability ( 340 / 174 /
44
/
122
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
Chemoresistance ( 302 / 152 /
57
/
93
)
IFN production ( 10 / 5 /
2
/
3
)
colony formation ( 559 / 285 /
74
/
200
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 71 / 36 /
25
/
10
)
EMT ( 1023 / 518 /
206
/
299
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 115 / 58 /
25
/
32
)
Invasion ( 4113 / 2082 /
679
/
1352
)
MET ( 18 / 10 /
8
/
)
Metastasis ( 1241 / 629 /
253
/
359
)
migration ( 3283 / 1657 /
535
/
1091
)
motility ( 217 / 111 /
34
/
72
)
NF-kB signaling ( 247 / 125 /
63
/
59
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 31 / 16 /
7
/
8
)
Paclitaxel resistance ( 73 / 37 /
13
/
23
)
Proliferation ( 4672 / 2356 /
759
/
1557
)
Radioresistance ( 149 / 76 /
27
/
46
)
Senescence ( 75 / 41 /
26
/
8
)
stemness ( 263 / 132 /
59
/
72
)
survival ( 136 / 70 /
24
/
42
)
Tamoxifen resistance ( 25 / 13 /
8
/
4
)
cisplatin resistance ( 380 / 191 /
65
/
124
)
doxorubicin resistance ( 93 / 47 /
15
/
31
)
ERK pathway (MAPK pathway) ( 203 / 102 /
33
/
68
)
etoposide ( 7 / 4 /
2
/
1
)
Liver metastasis ( 30 / 17 /
5
/
8
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 22 / 12 /
5
/
5
)
RAS signaling pathway ( 10 / 6 /
2
/
2
)
tumor growth ( 968 / 487 /
165
/
316
)
Lung metastasis ( 71 / 37 /
17
/
17
)
PI3K signaling ( 115 / 58 /
21
/
36
)
WNT signaling ( 408 / 205 /
89
/
114
)
Hedgehog (Hh) signaling ( 32 / 17 /
5
/
10
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
Response to genotoxic stress ( 6 / 4 /
2
/
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
docetaxel resistance ( 47 / 25 /
16
/
6
)
epirubicin resistance ( 5 / 3 /
2
/
)
JAK/STAT signaling ( 122 / 62 /
31
/
29
)
mTOR signaling ( 92 / 46 /
12
/
34
)
Necrosis ( 6 / 3 /
2
/
1
)
NOTCH signaling ( 91 / 46 /
23
/
22
)
P38 signaling ( 35 / 18 /
10
/
7
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 15 / 12 /
2
/
1
)
tumor progression ( 82 / 42 /
24
/
16
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
unfolded protein response ( 7 / 5 /
1
/
1
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
lipogenesis ( 25 / 13 /
1
/
11
)
TGF-beta signaling ( 460 / 255 /
104
/
101
)
Temozolomide (TMZ) resistance ( 42 / 21 /
6
/
15
)
Lapatinib resistance ( 6 / 3 /
1
/
2
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
)
T cell activation ( 3 / 2 /
1
/
)
Sorafenib resistance ( 40 / 20 /
6
/
14
)
glucose metabolism ( 18 / 9 /
3
/
6
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 28 / 14 /
8
/
6
)
Hippo signaling pathway ( 178 / 89 /
66
/
23
)
fibrosis ( 48 / 24 /
9
/
15
)
MAPK/JNK Signaling Pathway ( 24 / 12 /
5
/
7
)
Hypoxic response ( 12 / 7 /
5
/
)
Taxanes (paclitaxel and docetaxel) resistance ( 20 / 13 /
4
/
3
)
Trastuzumab resistance ( 20 / 10 /
6
/
4
)
TRAIL resistance ( 16 / 8 /
5
/
3
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
pyroptosis ( 16 / 8 /
7
/
1
)
Sunitinib resistance ( 8 / 4 /
4
/
)
Antiviral response ( 11 / 6 /
2
/
3
)
Response to oxidative stress ( 14 / 13 /
1
/
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 32 / 17 /
/
15
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Imatinib resistance ( 18 / 11 /
/
7
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
disease-free survival ( 3 / 2 /
/
1
)
EGFR-TKI resistance ( 4 / 3 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
Neratinib resistance ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
BCL2 inhibitors resistance ( 2 / 1 /
/
1
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
glycolysis ( 13 / 13 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Tyrosine kinase inhibitors (TKIs) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)